Safety Study of Topical Human FGF-1 for Wound Healing

NCT ID: NCT00916292

Last Updated: 2012-03-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-30
• Study Completion Date: 2013-09-30

Brief Summary

The purpose of the study is to see if FGF-1 is safe when applied topically to the surface of a wound.

Detailed Description

Dermal ulcers pose a significant healthcare problem in the United States, ultimately affecting 10-15% of the approximately 20 million patients with diabetes and a similar number of patients with chronic venous insufficiency. Dermal leg and foot ulcers can result from compromised arterial inflow, microvascular perfusion or venous outflow which can lead to amputation unless vascular perfusion is improved. FGF-1 for topical administration offers the possibility of improved microvascular perfusion by promoting the formation of new blood vessels in the wound bed resulting in enhanced development of granulation tissue and accelerated healing.

Conditions

Diabetic Foot Ulcers

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Low dose

Four subjects will receive low dose FGF-1

Group Type: EXPERIMENTAL

FGF-1 141

Intervention Type: DRUG

Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.

High Dose

Four subjects will receive high dose FGF-1

Group Type: EXPERIMENTAL

FGF-1 141

Intervention Type: DRUG

Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.

Interventions

FGF-1 141

Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.

Intervention Type: DRUG

FGF-1 141

Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Sign an informed consent form prior to the initiation of any study procedures. Subjects must be competent to give written informed consent.

2. Age must be between 18 to 75 years of age.

3. Female subject must be post-menopausal or sterilized, or if she is of childbearing potential, she is not breast feeding, and her serum pregnancy test is negative.

4. Subjects must be willing to change their wound dressings daily and demonstrate to study personnel the ability to follow the dressing care instructions indicated in the Appendix. Subjects considered eligible to enter the study must sign an informed consent form prior to the initiation of any study procedures. In the event that the subject must be withdrawn and is re-screened for study participation at a later date, a new informed consent form must be signed. Subjects must be competent to give written informed consent.

Exclusion Criteria

1. Subjects receiving radiation therapy, corticosteroids, immunosuppressive agents or chemotherapy.

2. Subjects who, at study entry, are taking systemic antibiotics.

3. Subjects who are immunosuppressed.

4. Subjects experiencing bacterial or viral infection or who may otherwise be febrile.

5. Past history or current presence of any type of cancer (except past history of basal cell carcinoma that is not on the limb being treated). Subjects with existing BCC will be excluded from the study.

6. Life expectancy of less than 1 year.

7. Active alcohol or drug abuse within 6 months prior to study entry.

8. Screening liver function tests of more than 2.0 times the upper limit of normal.

9. Serum creatinine of ≥ 2.5 mg/dl.

10. Hemoglobin A1c (HgbA1c) of >10%.

11. Exposure to any other investigational drugs or devices or participation in any other investigational studies within 30 days prior to study entry.

12. Any other medical, social, or geographical factor that would make it unlikely that the subject will comply with study procedures (e.g., alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or a history of non-compliance).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Phage Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Shawn Searle, MD

Role: PRINCIPAL_INVESTIGATOR

Dedicated Phase I

Locations

Dedicated Phase I

Phoenix, Arizona, United States

Countries

United States

Facility Contacts

Shawn Searle, MD

Role: primary

602-279-7300

Other Identifiers

Phage-W2009-01-1a

Identifier Type: -

Identifier Source: org_study_id